These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 925953)

  • 1. Comparative pharmacokinetics of coumarin anticoagulants XXXVI: Predicted steady-state patterns of prothrombin complex activity produced by equieffective doses of (R)-(+)- and (S)-(-)-warfarin in humans.
    Wingard LB; Levy G
    J Pharm Sci; 1977 Dec; 66(12):1790-1. PubMed ID: 925953
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative pharmacokinetics of coumarin anticoagulants XXXV: Examination of possible pharmacokinetic interaction between (R)-(+)- and (S)-(--)-warfarin in humans.
    Levy G; O'Reilly RA; Wingard LB
    J Pharm Sci; 1978 Jun; 67(6):867-8. PubMed ID: 660478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetics of coumarin anticoagulants. X. Relationship between distribution, elimination, and anticoagulant action of warfarin.
    Yacobi A; Wingard LB; Levy G
    J Pharm Sci; 1974 Jun; 63(6):868-72. PubMed ID: 4851098
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative pharmacokinetics of coumarin anticoagulants XLV: Pharmacokinetic and pharmacodynamic studies of acute interaction between warfarin and phenylbutazone in rats.
    Yacobi A; Lai CM; Levy G
    J Pharm Sci; 1980 Jan; 69(1):14-20. PubMed ID: 7354432
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative pharmacokinetics of coumarin anticoagulants XXIX: Elimination kinetics and anticoagulant activity of (S)-(-)-warfarin in rats before and after chronic administration.
    Yacobi A; Levy G
    J Pharm Sci; 1977 Sep; 66(9):1275-7. PubMed ID: 903865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.
    Awni WM; Hussein Z; Granneman GR; Patterson KJ; Dubé LM; Cavanaugh JH
    Clin Pharmacokinet; 1995; 29 Suppl 2():67-76. PubMed ID: 8620673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
    Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H
    Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictability of warfarin dose requirements: theoretical considerations.
    Sawyer WT
    J Pharm Sci; 1979 Apr; 68(4):432-4. PubMed ID: 438962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of warfarin enantiomers: a search for intrasubject correlations.
    Wingard LB; O'Reilly RA; Levy G
    Clin Pharmacol Ther; 1978 Feb; 23(2):212-7. PubMed ID: 620483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of warfarin at steady state.
    Routledge PA; Chapman PH; Davies DM; Rawlins MD
    Br J Clin Pharmacol; 1979 Sep; 8(3):243-7. PubMed ID: 497091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect of mealtime wine on the hypoprothrombinemia of oral anticoagulants.
    O'Reilly RA
    Am J Med Sci; 1979; 277(2):189-94. PubMed ID: 463946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The disposition of the enantiomers of warfarin following chronic administration to rats: relationship to anticoagulant response.
    Pratt SK; Winn MJ; Park BK
    J Pharm Pharmacol; 1989 Nov; 41(11):743-6. PubMed ID: 2576040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes.
    Ferrari M; Pengo V; Barolo M; Bezzo F; Padrini R
    Eur J Clin Pharmacol; 2017 Jun; 73(6):699-707. PubMed ID: 28382498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation.
    Svec JM; Coleman RW; Mungall DR; Ludden TM
    Ther Drug Monit; 1985; 7(2):174-80. PubMed ID: 4024210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects.
    Karim A; Tolbert D; Piergies A; Hubbard RC; Harper K; Wallemark CB; Slater M; Geis GS
    J Clin Pharmacol; 2000 Jun; 40(6):655-63. PubMed ID: 10868317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin therapy. 1.
    Deykin D
    N Engl J Med; 1970 Sep; 283(13):691-4. PubMed ID: 4916914
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of 3,4-benzo(a)pyrene on warfarin hypoprothrombinemia and disposition in the rat.
    Bachmann K; Tarloff J
    Toxicol Appl Pharmacol; 1977 Oct; 42(1):157-65. PubMed ID: 929599
    [No Abstract]   [Full Text] [Related]  

  • 19. Enantiomers of warfarin and vitamin K1 metabolism.
    Choonara IA; Haynes BP; Cholerton S; Breckenridge AM; Park BK
    Br J Clin Pharmacol; 1986 Dec; 22(6):729-32. PubMed ID: 3567019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects.
    Sanwald-Ducray P; Jamois C; Banken L
    J Cardiovasc Pharmacol; 2014 Feb; 63(2):152-7. PubMed ID: 24157957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.